$37.6 0.4 1.2%
Last Trade - 15/04/21
| Market Cap | £152.14bn |
| Enterprise Value | £172.34bn |
| Revenue | £30.40bn |
| Position in Universe | 46th / 6851 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 48,851 | 52,824 | 52,546 | 40,825 | 41,172 | 41,908 | 62,585 | 53,456 | -3.0% | ||
| -6.4 | +35.7 | +10.0 | -54.7 | +17.1 | +42.5 | +89.5 | -8.26 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | June 2, 1942 |
| Public Since | January 17, 1944 |
| No. of Shareholders: | 139,582 |
| No. of Employees: | 78,500 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE Global 100, S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector), |
| Exchange | New York Stock Exchange |
| Shares in Issue | 5,578,164,054 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 235 E 42ND ST, NEW YORK, 10017-5703, United States |
| Web | https://www.pfizer.com/ |
| Phone | +1 212 5732323 |
| Contact | () |
| Auditors | KPMG LLP |
As of 15/04/21, shares in Pfizer Inc are trading at $37.6, giving the company a market capitalisation of £152.14bn. This share price information is delayed by 15 minutes.
Shares in Pfizer Inc are currently trading at $37.6 and the price has moved by 10.27% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Pfizer Inc price has moved by -25.16% over the past year.
Of the analysts with advisory recommendations for Pfizer Inc, there are there are currently 2 "buy" , 15 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Pfizer Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Pfizer Inc is scheduled to issue upcoming financial results on the following dates:
The Pfizer Inc dividend yield is 4.04% based on the trailing twelve month period.
Last year, Pfizer Inc paid a total dividend of 1.52, and it currently has a trailing dividend yield of 4.04%. Looking ahead, Pfizer Inc has not announced an ex-dividend date yet.
Pfizer Inc has yet to annouce their ex-dividend date. The historic dividend yield on Pfizer Inc shares is currently 4.04%.
To buy shares in Pfizer Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Pfizer Inc are currently trading at $37.6, giving the company a market capitalisation of £152.14bn.
Here are the trading details for Pfizer Inc:
Based on an overall assessment of its quality, value and momentum, Pfizer Inc is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Pfizer Inc are currently priced at $37.6. At that level they are trading at 8.09% discount to the analyst consensus target price of 0.00.
Analysts covering Pfizer Inc currently have a consensus Earnings Per Share (EPS) forecast of 3.317 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pfizer Inc. Over the past six months, the relative strength of its shares against the market has been -13.16%. At the current price of $37.6, shares in Pfizer Inc are trading at 5.16% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pfizer Inc PE ratio based on its reported earnings over the past 12 months is 21.49. The shares are currently trading at $37.6.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pfizer Inc's management team is headed by:
Here are the top five shareholders of Pfizer Inc based on the size of their shareholding:
